GENOMICS ONE ACQUIRES PATENTS IN THE FIELD OF BIODEFENSE
GENOMICS ONE ACQUIRES PATENTS IN THE FIELD OF BIODEFENSE

LAVAL (Québec) CANADA, January 31, 2005 - Genomics One Corporation ("Genomics One") (TSX: GNX) announced today that the Corporation has signed a letter of intent to purchase patents from Valorisation-Recherche, a limited partnership, for the development of Mass Spectrometry equipment using the Metastable Atoms Bombardment (MAB) Technology. The Corporation will pay a sum of $350,000 CAN and 40,000 common shares of its capital stock for the patents, which will be used in the development and the manufacture of high-end Mass Spectrometry equipment.

The transaction between Genomics One and Valorisation-Recherche is subject to the approval of the TSX Venture Exchange, and consists of two equal installments of $175,000 each. Genomics One has already made a deposit payment of $50,000 and the remaining balance for the first installment of $125,000 will be paid at the closing of the transaction, on or before March 31, 2005. Genomics One will also issue 40,000 common shares of its capital stock to Valorisation-Recherche at closing. The second installment of $175,000 is payable at the first anniversary date of the closing. This transaction allows Genomics One to be the exclusive owner of the patents on the MAB Technology.

"This transaction will enable Genomics One to lay the foundation of a new BioDefense Division. Once we raise the required funds, we will aggressively pursue development and commercialization of the acquired patents. Our goal is to become an important player in Mass Spectrometers for the Life Sciences and BioDefence markets," said Dr. Suzanne L. Lebel, President and Chief Executive Officer of the Corporation. "Mass Spectrometers are presently in great demand in the fields of research, medical diagnostics, and biodefense. Mass Spectrometers enable research scientists to separate, recognize, and identify peptides, proteins, pathogen bacteria, viruses, and numerous dangerous and illegal chemical products such as gases, toxic liquids and solids, each of theses were formerly requiring a specific Mass Spectrometer. The patents acquired represent a commercial advantage of great importance for our Corporation which is already deeply involved in the field of Life Sciences. This new Genomics One equipment will have major advantages over its competition, first the Mass Spectrometer to be manufactured is compact equipment that can detect and identify both chemical and bacterial contaminants, second, the time of analysis is calculated in terms of a second depending on the type of analysis, third, the equipment generates reproducible results and fourth this equipment offers high resolution" explained Dr. Lebel.

"BioDefense is a rapidly growing market; it is a field of great importance to governments, industries, and societies worldwide. This acquisition will enable Genomics One to access a new global market, while expanding its offerings to its current Life Sciences clients" added Dr. Lebel.

About Genomics One
Founded in 1995, Genomics One Corporation is a Biotechnology company dedicated to supplying the Life Sciences market with cutting-edge technology and superior products. The Corporation’s goal is to ensure its core business continues to be the key to the success of its clients; who include scientists, physicians, graduate students and technicians working in every corner of the world in research and diagnostic laboratories. Genomics One sells products directly in North America through its wholly-owned subsidiaries BioCan Scientific Inc., (Canada) and BioCan Scientific Inc., (USA). For more information about Genomics One Corporation visit www.genomicsone.com.

The TSX Venture Exchange does not take responsibility for the adequacy or accuracy of this press release. Any and all statement that may be prospective shall not be interpreted as such.


Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotech News

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech